93 related articles for article (PubMed ID: 8626127)
1. Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes.
Boyd J
Gynecol Oncol; 1996 May; 61(2):163-5. PubMed ID: 8626127
[No Abstract] [Full Text] [Related]
2. [The regulation of estrogen and tamoxifen to bcl-2 oncogene in endometrial carcinoma].
Lai D; Zhu G; Zhou J
Zhonghua Fu Chan Ke Za Zhi; 1999 Oct; 34(10):615-7. PubMed ID: 11477803
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 and P53 expression in endometrial carcinoma.
Erkanli S; Eren F; Pekin S; Bagis T
J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
[TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2, bax-xL, and bcl-xS in endometrial and cervical tissues.
Mozzetti S; Ferrandina G; Marone M; D'Ingiullo F; Fruscella E; De Pasqua A; Mancuso S; Scambia G
Cancer Detect Prev; 2000; 24(6):536-41. PubMed ID: 11198267
[TBL] [Abstract][Full Text] [Related]
5. [Bcl-2 gene expression in endometrial carcinoma].
Sheng X; Song H; He X
Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):365-6. PubMed ID: 10921033
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
7. [Advances in the study of oncogenes and tumor suppressor genes in endometrial carcinoma].
Xue FX; Zhu YX; Jiao SZ
Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):559-62. PubMed ID: 7835134
[No Abstract] [Full Text] [Related]
8. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
9. [Bax gene expression in endometrial carcinoma].
Chao H; Sun J; Lu S
Zhonghua Zhong Liu Za Zhi; 2001 May; 23(3):214-6. PubMed ID: 11783089
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma.
Vaskivuo TE; Stenbäck F; Tapanainen JS
Cancer; 2002 Oct; 95(7):1463-71. PubMed ID: 12237915
[TBL] [Abstract][Full Text] [Related]
11. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry.
Porichi O; Nikolaidou ME; Apostolaki A; Tserkezoglou A; Arnogiannaki N; Kassanos D; Margaritis L; Panotopoulou E
Anticancer Res; 2009 Oct; 29(10):3977-82. PubMed ID: 19846939
[TBL] [Abstract][Full Text] [Related]
12. [Expression of p53 protein in women with endometrial cancer].
Ivanov S; Khadzhiolov N; Ivanov S
Akush Ginekol (Sofiia); 2001; 40(4):14-5. PubMed ID: 11803862
[TBL] [Abstract][Full Text] [Related]
13. Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma.
Boyd J
Prog Clin Biol Res; 1996; 394():151-73. PubMed ID: 8778795
[No Abstract] [Full Text] [Related]
14. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
15. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables.
Erdem O; Erdem M; Dursun A; Akyol G; Erdem A
Int J Gynecol Pathol; 2003 Jul; 22(3):254-60. PubMed ID: 12819392
[TBL] [Abstract][Full Text] [Related]
18. Endometrial carcinoma: pathology and genetics.
Prat J; Gallardo A; Cuatrecasas M; Catasús L
Pathology; 2007 Feb; 39(1):72-87. PubMed ID: 17365824
[TBL] [Abstract][Full Text] [Related]
19. bcl-2 expression and the development of endometrial carcinoma.
Chhieng DC; Ross JS; Ambros RA
Mod Pathol; 1996 Apr; 9(4):402-6. PubMed ID: 8729980
[TBL] [Abstract][Full Text] [Related]
20. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.
Nikaido T; Li SF; Shiozawa T; Fujii S
Cancer; 1996 Sep; 78(6):1248-53. PubMed ID: 8826947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]